Abstract
Intraoperative cell salvage (ICS) is an effective and safe intervention for patients with a high risk of postpartum hemorrhage (PPH) during elective or emergency Cesarean section. This prospective randomized controlled trial demonstrates that ICS can effectively clear tissue factors and alpha-fetoprotein, though it does not remove fetal hemoglobin.
Introduction
Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality globally. While allogeneic (donor) blood transfusions are the standard of care, they are often limited by supply, risk of transfusion-related infections, and potential for severe immune reactions.
Intraoperative Cell Salvage (ICS)—the process of collecting, washing, and reinfusing a patient’s own lost blood—is common in cardiac and orthopedic surgeries but has remained controversial in obstetrics due to the risk of amniotic fluid contamination. Clinicians have long feared that reinfusing fetal components (such as fetal red blood cells, tissue factor, or alpha-fetoprotein) could trigger life-threatening Amniotic Fluid Embolism (AFE) or cause maternal isoimmunization. This study provides high-quality clinical evidence on the safety and efficacy of modern ICS systems in managing high-risk PPH.
Methodology
The researchers conducted a prospective randomized controlled trial (RCT) involving 130 patients at high risk for PPH (due to conditions like placenta previa or twin pregnancies) undergoing Cesarean sections at the Haidian Maternal and Child Health Hospital in Beijing, China.
Patients were randomized into two groups:
- ICS Group (n=65): Lost blood was processed using the XTRA Autotransfusion System. This system centrifuges and washes red blood cells (RBCs) with saline before passing them through a leukocyte-removing filter for reinfusion.
- Control Group (n=65): Patients received standard allogeneic RBC transfusions if their hemoglobin dropped below 80 g/L.
The study tracked hematological markers (Hb, RBC count, hematocrit), coagulation function (PT, aPTT, TT, fibrinogen), and "fetal markers" (tissue factor, alpha-fetoprotein, and fetal hemoglobin) to assess cleansing efficiency.
The Intraoperative Cell Salvage (ICS) System
The ICS process is designed to recover autologous blood while minimizing the reinfusion of contaminants that could lead to complications.
As shown in the system illustration, blood is collected into a reservoir, processed through the autotransfusion system where it is washed with saline, and then filtered to remove white blood cells and other debris before being reinfused into the patient.
Key Results and Insights
Hematological and Coagulation Outcomes
The ICS group showed significantly higher increases in hemoglobin, RBC count, and hematocrit compared to the control group (p < 0.05). Notably, ICS patients maintained superior blood-clotting profiles. While the control group experienced a significant deterioration in coagulation function 24 hours post-surgery (prolonged PT and aPTT), the ICS group remained stable. This suggests that donor blood may contribute to a "dilution effect" or lacks the functional integrity of freshly processed autologous cells.
Selective Filtration and Safety
The ICS system proved to be a highly effective but selective sieve. It successfully removed Tissue Factor (a potent initiator of coagulation) and Alpha-fetoprotein (a marker for amniotic fluid). However, the study confirmed that ICS cannot distinguish between maternal and fetal red blood cells; fetal hemoglobin levels rose in maternal circulation post-reinfusion. Crucially, zero adverse events—specifically no cases of AFE or hypotension—were recorded in the ICS group, confirming the safety of the procedure in this cohort.
Reduced Donor Dependency
The use of ICS significantly reduced the need for allogeneic blood. Only 6.15% of the ICS group required supplemental donor blood or plasma, compared to 35.38% in the control group (p < 0.0001).
Discussion and Limitations
While the results are robust, certain limitations remain. Because the system reinfuses fetal RBCs, there is a lingering risk of Rh isoimmunization. This study excluded Rh-negative patients to mitigate this risk, but it remains a critical consideration for that population. Additionally, as a single-center study with 130 patients, larger multi-center trials are needed to detect extremely rare adverse events. Future research should also monitor patients through subsequent pregnancies to understand the long-term impact of reinfused fetal red cells.
In conclusion, ICS is a safe and highly effective alternative to donor blood for managing high-risk PPH, offering better preservation of coagulation function and reducing reliance on external blood supplies.
Summary updated